• Skip to main content
  • Skip to footer

Accuronix

Developing novel cancer therapies

  • Home
  • Founders
  • Approach
  • Contact

April 15, 2016

BioGenerator Company Accuronix Targets Pancreatic Cancer, EQstl.com

Pancreatic Cancer causes 40,000 deaths each year, with available chemotherapy regimens providing only an average of 6-11 months survival. WashU-born company Accuronix, founded by Dr. William Hawkins and Robert Mach, PhD. (now of the University of Pennsylvania), is taking on this difficult disease by developing novel therapies to selectively target cancer cells, increasing effectiveness and decreasing toxicity.

President and CEO of Accuronix, Dennis Schafer brings more than 30 years experience as a serial Biotech entrepreneur, participating in 12 startups throughout his career.

Read More

Filed Under: News

Footer

About Us

We are applying a novel drug-targeting technology to some of the most difficult problems in cancer therapy.

News & Publications
Financial Conflicts of Interest (FCOI)

Mission

With an initial focus in pancreatic cancer, the Company’s mission is to develop novel oncology therapies based on technology that selectively targets σ-2 receptors overexpressed on cancer cells

Partners

Washington University | University of Pennsylvania | BioGenerator

Contact Us

Accuronix Therapeutics
4340 Duncan Ave.
Suite 210
St. Louis, MO 63110

Contact
Bradley T. Keller, Ph.D.
President and CEO
[email protected]

Copyright © 2025 Accuronix.com · Powered by NeuConcept